To require the Secretary of Defense to establish a pilot program to evaluate novel pharmaceutical manufacturing technologies to reduce the reliance of the Department on foreign manufacturers for active pharmaceutical ingredients and key starting materials.
Synthetic Biology and Active Pharmaceutical Ingredients Act
This bill requires the Department of Defense (DOD) to establish a pilot program to support domestic manufacturing of critical pharmaceutical ingredients and their components through certain novel technology.
Specifically, DOD must establish a three-year program that uses technology involving synthetic biology to support domestic manufacturing of pharmaceutical ingredients and related incorporated materials that (1) are not available in a sufficient quantity or quality domestically, and (2) are strategically important to the United States.
Introduced in House
Introduced in House
Referred to the House Committee on Armed Services.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line